Skip To Main Content
Michaela C. Barbier on Muck Rack

Michaela C. Barbier

As seen in: PLOS
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Michaela C.

Contact Michaela C., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer

|
By Yuki Tomonaga, Dominik Menges, Henock G. Yebyo, Michaela C. Barbier
| PLOS
Scenario analyses When using the different HRs from the NMA by Menges et al. (including or excluding data of the ENZAMET and LATITUDE trials) (S13 Table in S2 Appendix), the ICER for ADT+abiraterone versus ADT+docetaxel increased to above EUR 50,000 per QALY gained, but stayed below the assumed WTP threshold (S15 Table in S2 Appendix).
Open in Who Shared Issue with article?
See all 1 articles